ArticleBlood advances2019
Clinicopathologic and genetic characterization of nonacute
Open access · goldAbstract read
In one paragraph
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 66 citations in OpenAlex.
- Two Decades ofCancers · 2026Review
- Chronic Myelomonocytic Leukemia: History, Pathobiology, Diagnostic Controversies, and Evolving Classification.Current hematologic malignancy reports · 2026Review
- Prospective feasibility study of peripheral blood for MRD detection in acute myeloid leukemia by flow cytometry.Blood advances · 2026Article
- [Myelodysplastic neoplasms with acute myeloid leukemia-like mutations: clinical features, molecular profiles, and prognosis].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States.Blood cancer discovery · 2025Article
- A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia.Blood cancer journal · 2025Article
- What Is Acute Myeloid Leukemia?EJHaem · 2025Review
- Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management.American journal of hematology · 2025Review
- [Dynamic changes in genetic mutations in myelodysplastic neoplasms with progressive disease and leukemic transformation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?The oncologist · 2025Review
- AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.Blood advances · 2025Article
- Article
- Recent advances in AML with mutated NPM1.International journal of hematology · 2024Review
- WT1 gene mutations impact post-transplant relapse in myelodysplastic syndrome with excess blasts 2 patients.Annals of hematology · 2024Article
- Infrequent Presentations of ChronicCancers · 2024Review
- Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.Blood cancer discovery · 2024Review
- Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study.Annals of hematology · 2023Article
- The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non-AML myeloid neoplasms.Genes, chromosomes & cancer · 2023Article
- Genetic, Phenotypic, and Clinical Heterogeneity of NPM1-Mutant Acute Myeloid Leukemias.Biomedicines · 2023Review
- [Outcome of allogeneic hematopoietic stem cell transplantation in 14 patients with NPM1-mutated myelodysplastic syndromes].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 1 country.
Sanjay S PatelDepartment of Pathology, Brigham and Women's Hospital, Boston, MA.
Caleb HoDivision of Hematopathology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-5448-4635
Ryan N PtashkinDivision of Hematopathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Sam SadighDivision of Hematopathology, Department of Pathology, Hospital of the University of Pennsylvania and Perelman School of Medicine, Philadelphia, PA.
Adam BaggDivision of Hematopathology, Department of Pathology, Hospital of the University of Pennsylvania and Perelman School of Medicine, Philadelphia, PA.
Julia T GeyerDivision of Hematopathology, Weill Cornell Medical College, New York, NY.
Mina L XuDepartment of Pathology and Laboratory Medicine and.
Thomas PrebetDivision of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.
Emily F MasonDepartment of Pathology, Vanderbilt University School of Medicine, Nashville, TN.
Adam C SeegmillerDepartment of Pathology, Vanderbilt University School of Medicine, Nashville, TN.
Elizabeth A MorganDepartment of Pathology, Brigham and Women's Hospital, Boston, MA.ORCID 0000-0001-5880-9337
David P SteensmaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Eric S WinerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Waihay J WongDepartment of Pathology, Brigham and Women's Hospital, Boston, MA.
Robert P HasserjianDepartment of Pathology, Massachusetts General Hospital, Boston, MA; and.
Olga K WeinbergDepartment of Pathology, Brigham and Women's Hospital, Boston, MA.
Brigham and Women's Hospital · USDana-Farber Cancer Institute · USHospital of the University of Pennsylvania · USMemorial Sloan Kettering Cancer Center · USVanderbilt University · USCornell University · USMassachusetts General Hospital · USYale University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MNCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA008748
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AFemaleHumansMaleMiddle AgedMutationMyelodysplastic SyndromesNuclear ProteinsNucleophosminPrognosisProportional Hazards ModelsProtein Tyrosine Phosphatase, Non-Receptor Type 11DNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanNPM1 protein, humanNuclear ProteinsNucleophosminProtein Tyrosine Phosphatase, Non-Receptor Type 11PTPN11 protein, humanTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.